107 related articles for article (PubMed ID: 23230395)
1. Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial.
Cornelius JR; Douaihy AB; Clark DB; Chung T; Wood DS; Daley D
J Dual Diagn; 2012 Sep; 8(3):200-204. PubMed ID: 23230395
[TBL] [Abstract][Full Text] [Related]
2. Mirtazapine in Comorbid Major Depression and Alcohol Use Disorder: A Long-Term Follow-Up Study.
Cornelius JR; Douaihy AB; Clark DB; Daley DC; Chung TA; Wesesky MA; Wood DS; Salloum I
J Addict Behav Ther Rehabil; 2013 Aug; 3(1):. PubMed ID: 25374892
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Cornelius JR; Chung T; Douaihy AB; Kirisci L; Glance J; Kmiec J; FitzGerald D; Wesesky MA; Salloum I
Psychiatry Res; 2016 Aug; 242():326-330. PubMed ID: 27327217
[TBL] [Abstract][Full Text] [Related]
4. A Review of the Literature of Mirtazapine in Co-Occurring Depression and an Alcohol Use Disorder.
Cornelius JR; Chung TA; Douaihy AB; Kirisci L; Glance J; Kmiec J; Wesesky MA; FitzGerald D; Salloum I
J Addict Behav Ther Rehabil; 2016; 5(4):. PubMed ID: 28393081
[TBL] [Abstract][Full Text] [Related]
5. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder.
Brunette MF; Akerman SC; Dawson R; O'Keefe CD; Green AI
Alcohol; 2016 Jun; 53():45-50. PubMed ID: 27256763
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
7. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study.
Yoon SJ; Pae CU; Kim DJ; Namkoong K; Lee E; Oh DY; Lee YS; Shin DH; Jeong YC; Kim JH; Choi SB; Hwang IB; Shin YC; Cho SN; Lee HK; Lee CT
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1196-201. PubMed ID: 16624467
[TBL] [Abstract][Full Text] [Related]
8. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
[TBL] [Abstract][Full Text] [Related]
9. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.
Honig A; Kuyper AM; Schene AH; van Melle JP; de Jonge P; Tulner DM; Schins A; Crijns HJ; Kuijpers PM; Vossen H; Lousberg R; Ormel J;
Psychosom Med; 2007; 69(7):606-13. PubMed ID: 17846258
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine in major depression with comorbid generalized anxiety disorder.
Goodnick PJ; Puig A; DeVane CL; Freund BV
J Clin Psychiatry; 1999 Jul; 60(7):446-8. PubMed ID: 10453798
[TBL] [Abstract][Full Text] [Related]
12. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
Davis R; Wilde MI
CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
[TBL] [Abstract][Full Text] [Related]
13. Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial.
Hashimoto T; Shiina A; Hasegawa T; Kimura H; Oda Y; Niitsu T; Ishikawa M; Tachibana M; Muneoka K; Matsuki S; Nakazato M; Iyo M
Ann Gen Psychiatry; 2016; 15():27. PubMed ID: 27777607
[TBL] [Abstract][Full Text] [Related]
14. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA;
CNS Drugs; 2010 Jan; 24(1):35-53. PubMed ID: 20030418
[TBL] [Abstract][Full Text] [Related]
15. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Cornelius JR; Bukstein OG; Douaihy AB; Clark DB; Chung TA; Daley DC; Wood DS; Brown SJ
Drug Alcohol Depend; 2010 Nov; 112(1-2):39-45. PubMed ID: 20576364
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
[TBL] [Abstract][Full Text] [Related]
17. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
Schüle C; Baghai TC; Eser D; Hecht S; Hermisson I; Born C; Häfner S; Nothdurfter C; Rupprecht R
World J Biol Psychiatry; 2007; 8(2):112-22. PubMed ID: 17455104
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial.
Han C; Pae CU; Lee BH; Ko YH; Masand PS; Patkar AA; Joe SH; Jung IK
Clin Drug Investig; 2008; 28(4):251-61. PubMed ID: 18345715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
